相关实验视频

Updated: Jul 1, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

针对高风险多发性骨髓瘤基因型,使用优化的抗CD70CAR-T细胞

Corynn Kasap^1,2, Adila Izgutdina², Bonell Patiño-Escobar²

¹Dept. of Medicine, Division of Hematology/Oncology, University of California, San Francisco, CA.

bioRxiv : the preprint server for biology

|March 11, 2024

概括

研究人员确定CD70是高风险多发性骨髓瘤的一个有希望的目标. 一种基于CD27的针对CD70的新型CAR-T疗法显示出卓越的扩张和疗效,提供了一种新的治疗途径.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

患有高风险细胞遗传学的多发性骨髓瘤患者尽管向BCMA的CAR-T疗法,但结果不佳.
迫切需要新的治疗策略来克服这些患者的耐药性和复发.

研究的目的:

在高风险多发性骨髓瘤中高调的新型细胞表面抗原的识别.
开发和评估一种优化的化学抗原受体T细胞 (CAR-T) 疗法,针对新发现的抗原.

主要方法:

基于CD27的抗CD70CAR-T结构的结构引导设计.
在体内扩展研究比较基于CD27的CAR-T与基于scFv的CAR.
使用机器学习进行表观遗传学分析,以识别CD70表达的驱动因素.
开发双重定位的CAR-T (CD70/BCMA) 系统.

主要成果:

CD70被确定为高风险髓瘤瘤中特异上调的抗原.
与基于scFv的CARs相比,基于CD27的抗CD70CAR-T在体内扩张率提高了80倍以上.
机器学习预测了驱动CD70上调的关键转录因子和网络.
双重准的CAR-T显示出克服抗原逃逸的潜力.

结论:

CD70是高风险多发性骨髓瘤的一个有前途的治疗点.
基于CD27的优化CAR-T设计提供了更高的效率和扩展性.
向CD70代表了一种可行的策略,以改善结局并克服多发性骨髓瘤的耐药性,具有临床转化潜力.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...